JBC Focus on PI3-Kinase with Echelon

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


A more recent version of this article appeared on September 3, 2004
This Article
Right arrow Full Text (Accepted Manuscript)
Right arrow All Versions of this Article:
279/36/37219    most recent
C400258200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dai, S.
Right arrow Articles by Abu-Amer, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dai, S.
Right arrow Articles by Abu-Amer, Y.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Papers In Press, published online ahead of print July 13, 2004
J. Biol. Chem, 10.1074/jbc.C400258200
Submitted on June 3, 2004
Revised on June 29, 2004
Accepted on July 13, 2004

The IKK inhibitor, NEMO-binding domain peptide, blocks osteoclastogenesis and bone erosion in inflammatory arthritis

Simon Dai, Teruhisa Hirayama, Sabiha Abbas, and Yousef Abu-Amer

Department of Orthopedic Surgery, Washington University, St. Louis, MO 63110

Corresponding Author: abuamery{at}msnotes.wustl.edu

Activation of the transcription factor NF-kappa B leads to expression of ample genes that regulate inflammatory and osteoclastogenic responses and requires induction of Ikappa B kinase (IKK) complex that phosphorylates the NF-kappa B inhibitory protein Ikappa B and leads to its dissociation form the NF-kappa B complex, thus permitting nuclear translocation of NF-kappa B. The IKK complex contains several factors primarily IKKalpha , IKKbeta , and the regulatory kinase IKKgamma , also known as NEMO. NEMO regulates the IKK complex activity through its binding to carboxyl-terminal region of the IKKalpha and IKKbeta , termed NEMO-binding domain (NBD). In this regard, a cell-permeable NBD peptide has been shown to block association of NEMO with the IKK complex, inhibits cytokine-induced activation of NF-kappa B, and ameliorates inflammatory responses. Given the pivotal role of cytokine-induced NF-kappa B in osteoclastogenesis and inflammatory bone loss, we deduced that cell-permeable TAT-NBD peptide may hinder osteoclastogenesis and bone erosion in inflammatory arthritis. Using NBD peptides, we show that wild type, but not mutant, NBD blocks IKK activation and reduces TNF-induced promoter and DNA-binding activities of NF-kappa B and inhibits cytokine-induced osteoclast formation by osteoclast precursors (OCPs). Consistent with the key role of NF-kappa B in osteolytic and inflammatory responses in vivo, wild type TAT-NBD peptide administered into mice prior to induction of inflammatory arthritis efficiently blocks in vivo osteoclast recruitment, inhibits focal bone erosion, and ameliorates inflammatory responses in the joints of arthritic mice. The mutant NBD peptide fails to execute these functions. These results provide strong evidence that IKKs are potent regulators of cytokine-induced osteoclastogenesis and inflammatory arthritis. More importantly, blockade of NEMO assembly with the IKK complex is a viable strategy to avert inflammatory osteolysis.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
J. E. Otero, S. Dai, D. Foglia, M. Alhawagri, J. Vacher, M. Pasparakis, and Y. Abu-Amer
Defective Osteoclastogenesis by IKK{beta}-null Precursors Is a Result of Receptor Activator of NF-{kappa}B Ligand (RANKL)-induced JNK-dependent Apoptosis and Impaired Differentiation
J. Biol. Chem., September 5, 2008; 283(36): 24546 - 24553.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
S. Vaira, T. Johnson, A. C. Hirbe, M. Alhawagri, I. Anwisye, B. Sammut, J. O'Neal, W. Zou, K. N. Weilbaecher, R. Faccio, et al.
RelB is the NF-{kappa}B subunit downstream of NIK responsible for osteoclast differentiation
PNAS, March 11, 2008; 105(10): 3897 - 3902.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. H. Dave, J. S. Tilstra, K. Matsuoka, F. Li, T. Karrasch, J. K. Uno, A. R. Sepulveda, C. Jobin, A. S. Baldwin, P. D. Robbins, et al.
Amelioration of Chronic Murine Colitis by Peptide-Mediated Transduction of the I{kappa}B Kinase Inhibitor NEMO Binding Domain Peptide
J. Immunol., December 1, 2007; 179(11): 7852 - 7859.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
S. L. Teitelbaum
Osteoclasts: What Do They Do and How Do They Do It?
Am. J. Pathol., February 1, 2007; 170(2): 427 - 435.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
H. Ichikawa, A. Murakami, and B. B. Aggarwal
1'-Acetoxychavicol Acetate Inhibits RANKL-Induced Osteoclastic Differentiation of RAW 264.7 Monocytic Cells by Suppressing Nuclear Factor-{kappa}B Activation
Mol. Cancer Res., April 1, 2006; 4(4): 275 - 281.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. Takada, A. Gillenwater, H. Ichikawa, and B. B. Aggarwal
Suberoylanilide Hydroxamic Acid Potentiates Apoptosis, Inhibits Invasion, and Abolishes Osteoclastogenesis by Suppressing Nuclear Factor-{kappa}B Activation
J. Biol. Chem., March 3, 2006; 281(9): 5612 - 5622.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
Y. Takada, H. Ichikawa, V. Badmaev, and B. B. Aggarwal
Acetyl-11-Keto-beta-Boswellic Acid Potentiates Apoptosis, Inhibits Invasion, and Abolishes Osteoclastogenesis by Suppressing NF-{kappa}B and NF-{kappa}B-Regulated Gene Expression.
J. Immunol., March 1, 2006; 176(5): 3127 - 3140.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
H. Ichikawa and B. B. Aggarwal
Guggulsterone Inhibits Osteoclastogenesis Induced by Receptor Activator of Nuclear Factor-{kappa}B Ligand and by Tumor Cells by Suppressing Nuclear Factor-{kappa}B Activation
Clin. Cancer Res., January 15, 2006; 12(2): 662 - 668.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
M. A. Pattoli, J. F. MacMaster, K. R. Gregor, and J. R. Burke
Collagen and Aggrecan Degradation Is Blocked in Interleukin-1-Treated Cartilage Explants by an Inhibitor of I{kappa}B Kinase through Suppression of Metalloproteinase Expression
J. Pharmacol. Exp. Ther., October 1, 2005; 315(1): 382 - 388.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
Y. Dai, M. Rahmani, P. Dent, and S. Grant
Blockade of Histone Deacetylase Inhibitor-Induced RelA/p65 Acetylation and NF-{kappa}B Activation Potentiates Apoptosis in Leukemia Cells through a Process Mediated by Oxidative Damage, XIAP Downregulation, and c-Jun N-Terminal Kinase 1 Activation
Mol. Cell. Biol., July 1, 2005; 25(13): 5429 - 5444.
[Abstract] [Full Text] [PDF]


Home page
IBMS BoneKEyHome page
E. Seeman and G. J. Strewler
Clinical and Basic Research Papers - August 2004 Selections
IBMS BoneKEy, October 1, 2004; 1(10): 1 - 3.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2004 by the American Society for Biochemistry and Molecular Biology.